Inhibition of the ubiquitin-proteasome system sensitizes TRAIL-resistant prostate cancer cells by up-regulation of death receptor 5

Molecular Medicine Reports

Volumn 4, Issue 6, 2011, Pages 1255-1259

  Lee, You Jin ^a   Seol, Jae Won ^a   Jeong, Jae Kyo ^a   Moon, Myung Hee ^a   Park, Sang Youel ^a  

^a Chonbuk National University   (South Korea)

Author keywords

ALLN; Apoptosis; Death receptor 5; Proteasome inhibitor; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

CASPASE 3; CASPASE 8; DEATH RECEPTOR 5; N ACETYL LEUCINYL LEUCINYL NORLEUCINAL; PROTEASOME INHIBITOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UBIQUITIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL STRAIN LNCAP; CELL STRUCTURE; CELL VIABILITY; CLINICAL TRIAL; CONTROLLED STUDY; DRUG SENSITIZATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; CASPASE 3; CASPASE 8; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUPEPTINS; MALE; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UBIQUITIN; UP-REGULATION;

EID: 80053110084     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.558     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin 57: 43-66, 2007.
2. Griffith TS, Anderson RD, Davidson BL, Williams RD and Ratliff TL: Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J. Immunol 165: 2886-2894, 2000. (Pubitemid 30660741)
3. Walczak H, Miller RE, Ariail K, et al: Tumoricidal activity of tumor necrosis factor-related apoptosis- inducing ligand in vivo. Nat Med 5: 157-163, 1999. (Pubitemid 29068521)
4. Malhi H and Gores GJ: TRAIL resistance results in cancer progression: a TRAIL to perdition? Oncogene 25: 7333-7335, 2006. (Pubitemid 44853423)
5. Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R and Olumi AF: Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res 64: 7086-7091, 2004. (Pubitemid 39331021)
6. Bucur O, Ray S, Bucur MC and Almasan A: APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy. Front Biosci 11: 1549-1568, 2006. (Pubitemid 43253441)
7. Ishizawa J, Yoshida S, Oya M, et al: Inhibition of the ubiquitin-proteasome pathway activates stress kinases and induces apoptosis in renal cancer cells. Int J Oncol 25: 697-702, 2004.
8. An WG, Hwang SG, Trepel JB and Blagosklonny MV: Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 14: 1276-1283, 2000. (Pubitemid 30445036)
9. Inoue T, Shiraki K, Fuke H, et al: Proteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathway. Anticancer Drugs 17: 261-268, 2006.
10. Nawrocki ST, Carew JS, Pino MS, et al: Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 65: 11658-11666, 2005. (Pubitemid 41821726)
11. Johnson TR, Stone K, Nikrad M, et al: The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 22: 4953-4963, 2003.
12. Sayers TJ, Brooks AD, Koh CY, et al: The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 102: 303-310, 2003. (Pubitemid 36759669)
13. Sohn D, Totzke G, Essmann F, Schulze-Osthoff K, Levkau B and Janicke RU: The proteasome is required for rapid initiation of death receptor-induced apoptosis. Mol Cell Biol 26: 1967-1978, 2006.
14. Seol DW and Billiar TR: Cysteine 230 modulates tumor necrosis factor-related apoptosis-inducing ligand activity. Cancer Res 60: 3152-3154, 2000.
15. Seol DW and Billiar TR: A caspase-9 variant missing the catalytic site is an endogenous inhibitor of apoptosis. J Biol Chem 274: 2072-2076, 1999.
16. Park SY, Billiar TR and Seol DW: Hypoxia inhibition of apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Biochem Biophys Res Commun 291: 150-153, 2002. (Pubitemid 34681151)
17. Seol DW, Li J, Seol MH, Park SY, Talanian RV and Billiar TR: Signaling events triggered by tumor necrosis factor-related apoptosis- inducing ligand (TRAIL): caspase-8 is required for TRAIL-induced apoptosis. Cancer Res 61: 1138-1143, 2001. (Pubitemid 32174436)
18. Lu M, Dou QP, Kitson RP, Smith DM and Goldfarb RH: Differential effects of proteasome inhibitors on cell cycle and apoptotic path-ways in human YT and Jurkat cells. J Cell Biochem 97: 122-134, 2006. (Pubitemid 43050184)
19. Yin D, Zhou H, Kumagai T, et al: Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 24: 344-354, 2005. (Pubitemid 40188583)
20. Ling YH, Liebes L, Ng B, et al: PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 1: 841-849, 2002.
21. Wente MN, Eibl G, Reber HA, Friess H, Buchler MW and Hines OJ: The proteasome inhibitor MG132 induces apoptosis in human pancreatic cancer cells. Oncol Rep 14: 1635-1638, 2005.
22. Brooks AD, Ramirez T, Toh U, et al: The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to apo2L/TRAIL-mediated apoptosis. Ann N Y. Acad Sci 1059: 160-167, 2005. (Pubitemid 43211618)
23. Ganten TM, Koschny R, Haas TL, et al: Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 42: 588-597, 2005. (Pubitemid 41233651)
24. Lashinger LM, Zhu K, Williams SA, Shrader M, Dinney CP and McConkey DJ: Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res 65: 4902-4908, 2005. (Pubitemid 40740830)
25. Mlynarczuk I, Hoser G, Grzela T, et al: Augmented pro-apoptotic effects of TRAIL and proteasome inhibitor in human promonocytic leukemic U937 cells. Anticancer Res 21: 1237-1240, 2001. (Pubitemid 32494237)
26. He Q, Huang Y and Sheikh MS: Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells. Oncogene 23: 2554-2558, 2004. (Pubitemid 38520752)
27. Kim OH, Lim JH, Woo KJ, et al: Influence of p53 and p21Waf1 expression on G2/M phase arrest of colorectal carcinoma HCT116 cells to proteasome inhibitors. Int J Oncol 24: 935-941, 2004.
28. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A and Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 271: 12687-12690, 1996. (Pubitemid 26175834)
29. Wiley SR, Schooley K, Smolak PJ, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682, 1995. (Pubitemid 26091143)
30. Yoshida T, Shiraishi T, Nakata S, et al: Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res 65: 5662-5667, 2005. (Pubitemid 40911167)
31. Zhu H, Guo W, Zhang L, et al: Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation. Cancer Biol Ther 4: 781-786, 2005. (Pubitemid 41351180)
32. Hougardy BM, Maduro JH, Van der Zee AG, et al: Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. Int J Cancer 118: 1892-1900, 2006.